Shares in Petach Tikva, Israel headquartered Teva Pharmaceutical Industries Ltd climbed 0.58%, ending Thursday's trading session at $37.96. The stock recorded a trading volume of 4.97 million shares. The Company's shares have gained 2.48% in the last one month and 4.72% on an YTD basis. The stock is trading 0.97% below its 50-day moving average. Moreover, shares of Teva Pharmaceutical Industries, which develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide, have a Relative Strength Index (RSI) of 56.50.
On January 03rd, 2017, research firm Maxim Group reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $52 a share to $49 a share.
On January 05th, 2017, Teva Pharmaceutical Industries announced that it will host 2017 business outlook conference call and live webcast on January 06th, 2017 at 8:00 a.m. ET. TEVA complete research report is just a click away and free at:
Dublin, Ireland headquartered Endo International PLC's stock declined 0.90%, closing the day at $17.54 with a total trading volume of 3.58 million shares. The Company's shares have advanced 10.52% in the last month and 6.50% since the start of this year. The stock is trading 4.49% above its 50-day moving average. Additionally, shares of Endo International, which develops, manufactures, and distributes pharmaceutical products and devices worldwide, have an RSI of 64.88.
On December 21st, 2016, Endo International announced that it has appointed Patrick Barry as Senior Vice President, US Branded Pharmaceuticals, effective immediately; and Matthew Davis, M.D., R.Ph., as Senior Vice President, Research and Development Branded Pharmaceuticals, effective January 03rd, 2017.
Yesterday, research firm Citigroup downgraded the Company's stock rating from 'Buy' to 'Neutral'. The complimentary report on ENDP can be downloaded at:
On Thursday, shares in Dublin, Ireland-based Amarin Corp. PLC recorded a trading volume of 2.41 million shares, which was higher than their three months average volume of 2.19 million shares. The stock ended the day 2.24% lower at $3.06. The Company's shares are trading above their 200-day moving average by 18.51%. Furthermore, shares of Amarin, which focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the US, have an RSI of 47.89.
On January 05th, 2017, Amarin provided a business update, including an update on 2016 revenue guidance. The Company noted that continued growth in both new and recurring Vascepa prescriptions in Q4 2016 resulted in increased market share and directly supported record revenue levels for Q4 and FY16. Amarin estimates FY16 product revenues, on a GAAP basis subject to audit, modestly exceeded $125 million, representing growth of more than 50% over reported FY15 net product revenue of $81 million. Amarin ended 2016 with approximately $98 million in cash and approximately $20 million in net accounts receivable. Amarin also has $15.1 million of outstanding exchangeable debt which, may be put to the Company on January 19th, 2017. Sign up for your complimentary research report on AMRN at:
Carlsbad, California headquartered Ionis Pharmaceuticals Inc.'s stock dropped 4.56%, finishing yesterday's session at $47.09. A total volume of 3.53 million shares was traded, which was above their three months average volume of 2.44 million shares. The Company's shares have advanced 2.37% in the last one month and 29.44% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 11.34% and 35.78%, respectively. Additionally, shares of Ionis Pharma, which focuses on developing drugs for patients with severe and rare diseases, have an RSI of 52.25.
On December 28th, 2016, research firm BMO Capital Markets reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $61 a share to $68 a share.
On January 04th, 2017, Ionis announced positive data from a Phase 2 study of IONIS-GCGRRx in 79 patients with type 2 diabetes. In this study, patients with type 2 diabetes uncontrolled on stable, maximal metformin therapy treated with IONIS-GCGRRx achieved robust and sustained, statistically significant improvements in hemoglobin A1c (HbA1c) and other measures of glucose control after 26 weeks of treatment. Get free access to your research report on IONS at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA